Frank Rimerman Advisors LLC Sells 6,009 Shares of Abbott Laboratories $ABT

Frank Rimerman Advisors LLC decreased its position in Abbott Laboratories (NYSE:ABT) by 26.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,041 shares of the healthcare product maker’s stock after selling 6,009 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Abbott Laboratories were worth $2,135,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Cloud Capital Management LLC bought a new position in Abbott Laboratories in the 3rd quarter worth $29,000. Guerra Advisors Inc bought a new stake in Abbott Laboratories during the third quarter valued at about $31,000. Delos Wealth Advisors LLC acquired a new stake in shares of Abbott Laboratories in the second quarter valued at about $32,000. Bridge Generations Wealth Management LLC acquired a new stake in shares of Abbott Laboratories in the third quarter valued at about $33,000. Finally, Copia Wealth Management bought a new position in shares of Abbott Laboratories in the third quarter worth about $38,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Precision Oncology tests are now integrated into Flatiron Health’s OncoEMR, giving more than 1,600 community cancer centers and ~4,700 providers the ability to order and receive Abbott test results inside their clinical workflow — a direct adoption catalyst for tests such as Oncotype DX, OncoExTra and Oncodetect that can lift diagnostics volume and recurring revenue. Abbott expands access to Precision Oncology
• Positive Sentiment: Abbott is a strategic investor in Whoop’s $575M Series G round (company valued at ~$10.1B). That stake gives Abbott optionality in wearable/consumer biometric data and potential commercial partnerships as Whoop scales globally and eyes an IPO — a complementary play to Abbott’s diabetes and consumer health franchises. Whoop raises $575M, adds Abbott as strategic investor
• Positive Sentiment: Industry research flags the global medical nutrition market growing to ~$31.1B by 2035, with Abbott named among key innovators — a favorable long-term demand backdrop for Abbott’s Nutrition segment once it stabilizes. Global Medical Nutrition Market to Reach USD 31.1 Billion by 2035
• Neutral Sentiment: Analyst note: BTIG trimmed its price target from $140 to $131 but maintained a Buy rating — a modest near-term view change but still a constructive stance implying upside from current levels. BTIG lowers ABT price target
• Neutral Sentiment: Recent analyst and media coverage highlights a mixed fundamental picture: Nutrition sales have pressured near-term growth, but Medical Devices (including FreeStyle Libre CGM and structural heart/electrophysiology businesses) remain strong; management is executing turnaround plans and pursuing the Exact Sciences acquisition — important long-term catalysts but with near-term execution risk. A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
• Negative Sentiment: Price action & volatility: recent trading showed a pullback to near 52‑week lows amid sector rotation and nutrition weakness, which has pressured sentiment even though core businesses remain solid. Short-term selling and investor rotation remain risks. Abbott (ABT) Dips More Than Broader Market

Insider Buying and Selling at Abbott Laboratories

In related news, EVP Mary K. Moreland sold 613 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the sale, the executive vice president owned 104,291 shares of the company’s stock, valued at $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the transaction, the executive vice president directly owned 146,377 shares of the company’s stock, valued at $16,918,253.66. This trade represents a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,055 shares of company stock worth $353,097 in the last 90 days. 0.46% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ABT has been the subject of several recent analyst reports. Raymond James Financial decreased their target price on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Leerink Partners cut their price target on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. Evercore reduced their price objective on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Oppenheimer lowered their price objective on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Finally, Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $135.68.

Abbott Laboratories Stock Performance

ABT opened at $102.59 on Wednesday. The stock’s 50 day simple moving average is $110.05 and its 200-day simple moving average is $121.57. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The stock has a market cap of $178.68 billion, a PE ratio of 27.58, a P/E/G ratio of 1.63 and a beta of 0.74. Abbott Laboratories has a 1 year low of $100.88 and a 1 year high of $139.06.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same period last year, the business earned $1.34 earnings per share. Abbott Laboratories’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.